High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon α for chronic hepatitis C virus infection

Liver International

Volumn 28, Issue 1, 2008, Pages 39-46

  Schreuder, Tim C M A ^a   Gelderblom, Huub C ^a   Weegink, Christine J ^a   Hamann, Dörte ^b   Reesink, Henk W ^a   Devries, J Hans ^c   Hoekstra, Joost B L ^c   Jansen, Peter L M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Sanquin Diagnostics at CLB ^*  (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Autoimmune; Diabetes mellitus; Hepatitis C; Interferon

Indexed keywords

ALPHA INTERFERON; AMANTADINE; ANTIDIABETIC AGENT; AUTOANTIBODY; C PEPTIDE; GLUCAGON; GLUCOSE; INSULIN; LEUKOCYTE ANTIGEN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL PROTOCOL; DRUG MEGADOSE; ETHNICITY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HEPATITIS C; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTPATIENT; POLYURIA; SCREENING; SEX DIFFERENCE; SIDE EFFECT; SYMPTOM; THIRST;

BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DNA PROBES, HLA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 37449007676     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01610.x     Document Type: Article

References (33)

1. Dienstag JL, McHutchison JG. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
2. Mandac JC, Chaudhry S, Sherman KE, et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification. Hepatology 2006; 43: 661-72.
3. Fabris P, Floreani A, Tositti G, et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003; 18: 549-58.
4. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340: 548.
5. Cozzolongo R, Betterle C, Fabris P, et al. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006; 18: 689-92.
6. Christensen UB, Krogsgaard K. Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin. Ugeskr Laeger 2004; 166: 1024-5.
7. Primo Vera J. Pegylated-interferon-induced diabetes mellitus type 1 in two patients with chronic hepatitis C. Gastroenterol Hepatol 2004; 27: 69.
8. Sasso FC, Carbonara O, Di Micco P, et al. A case of autoimmune polyglandular syndrome developed after interferon-alpha therapy. Br J Clin Pharmacol 2003; 56: 238-9.
9. Schories M, Peters T, Rasenack J, et al. Autoantibodies against islet cell antigens and type 1 diabetes after treatment with interferon-alpha. Dtsch Med Wochenschr 2004; 129: 1120-4.
10. Jabr FI, Ordinario MM. Sudden onset of diabetic ketoacidosis during pegylated interferon alfa therapy. Am J Med 2003; 115: 158-9.
11. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996; 24: 38-47.
12. Zein CO, Levy C, Basu A, et al. Chronic hepatitis C and type II diabetes mellitus: A prospective cross-sectional study. Am J Gastroenterol 2005; 100: 48-55.
13. Mehta SH, Brancati FL, Sulkowski MS, et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
14. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
15. Lo Iacono O, Venezia G, Petta S, et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1181-91.
16. Kawaguchi T, Ide T, Taniguchi E, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 2007; 102: 570-6.
17. Simo R, Lecube A, Genesca J, et al. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care 2006; 29: 2462-6.
18. Tai TY, Lu JY, Chen CL, et al. Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C. J Endocrinol 2003; 178: 457-65.
19. Mire-Sluis AR, Gaines Das R, Lernmark A. The world health organization international collaborative study for islet cell antibodies. Diabetologia 2000; 43: 1282-92.
20. Faber OK, Binder C. C-peptide response to glucagons. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977; 26: 605-10.
21. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29: S43-8.
22. Devendra D, Jasinski J, Melanitou E, et al. Interferon-alpha as a mediator of polyinosinic: Polycytidylic acid-induced type 1 diabetes. Diabetes 2005; 54: 2549-56.
23. Devendra D, Eisenbarth GS. Interferon alpha-a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 2004; 111: 225-33.
24. Stewart TA, Hultgren B, Huang X, et al. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993; 260: 1942-6.
25. Chakrabarti D, Hultgren B, Stewart TA. IFN-alpha induces autoimmune T cells through the induction of intracellular adhesion molecule-1 and B7.2. J Immunol 1996; 157: 522-8.
26. Huang X, Hultgren B, Dybdal N, et al. Islet expression of interferon-alpha precedes diabetes in both the BB rat and streptozotocin-treated mice. Immunity 1994; 1: 469-78.
27. Foulis AK, Farquharson MA, Meager A. Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 1987; 2: 1423-7.
28. Huang X, Yuang J, Goddard A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995; 44: 658-64.
29. Atkinson MA, Eisenbarth GS. Type 1 diabetes: New perspectives on disease pathogenesis and treatment. Lancet 2001; 358: 221-9.
30. Lecube A, Hernandez C, Genesca J, et al. Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis. Diabetes Care 2006; 29: 1140-9.
31. Lecube A, Hernandez C, Genesca J, et al. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care 2006; 29: 1096-101.
32. Knobler H, Schattner A. TNF-{alpha}, chronic hepatitis C and diabetes: A novel triad. Q J Med 2005; 98: 1-6.
33. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3-20.